Docetaxel 100 versus 80 mg/m2 as adjuvant treatments of early breast cancer: An exploratory analysis of a randomised trial

Annals of Oncology

Volumn 20, Issue 3, 2009, Pages 595-596

  Bono, Petri ^a   Kellokumpu Lehtinen, P L ^b   Alanko, T ^a   Kokko, R ^c   Asola, R ^d   Turpeenniemi Hujanen, T ^e   Jyrkkio S ^f   Kataja, V ^g   Leinonen, M ^h   Joensuu, H ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c KANTA HÄME CENTRAL HOSPITAL   (Finland)

^d SATAKUNTA CENTRAL HOSPITAL   (Finland)

^e OULU UNIVERSITY HOSPITAL   (Finland)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

^g VAASA CENTRAL HOSPITAL   (Finland)

^h 4Pharma Ltd   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; TRASTUZUMAB;

ADJUVANT THERAPY; ANTIBIOTIC PROPHYLAXIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG TOLERABILITY; EARLY CANCER; FEBRILE NEUTROPENIA; HUMAN; LETTER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; TAXOIDS;

EID: 61649101245     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn771     Document Type: Letter

References (2)

1. Harvey V, Mouridsen H, Semiglazov V et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 2006; 24: 4963-4970.
2. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.